ALGRX 3268 |
XYLOCAINE |
VAGISIL |
LIDOPEN |
LIGNOCAINE |
OCTOCAINE |
LIDOCAINE |
ORAQIX |
NSC-40030 |
XYLODASE |
LIGNOCAINE HCL |
IONTOCAINE |
LMX 4 |
LIDOCATON |
ANESTACON |
DENTIPATCH |
ZTLIDO |
ALGRX-3268 |
ALPHACAINE |
XYLOTOX |
EMBOLEX |
LIGNOSTAB |
LIDODERM |
Α-DIETHYLAMINO-2,6-DIMETHYLACETANILIDE |
2-(DIETHYLAMINO)-N-(2,6-DIMETHYLPHENYL)ACETAMIDE |
ALPHA-DIETHYLAMINO-2,6-DIMETHYLACETANILIDE |
2-(DIETHYLAMINO)-2',6'-ACETOXYLIDIDE |
XYLOCAINE® |
chemidplus:137-58-6 |
rxcui:6387 |
pubchem.compound:3676 |
chembl:CHEMBL79 |
drugbank:00281 |
Drug Indications | for treatment of pelvic pain of bladder origin and interstitital cystitis |
Drug Indications | for treatment of premature ejaculation |
Drug Indications | anestethic |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | anesthetic |
Drug Class | anesthetics, local |
Drug Class | anti-arrhythmia agents |
Year of Approval | approved before 1982 |
blocker (inhibitory) |
inhibitor (inhibitory) |
Trial Name | ALGRX 3268,Zingo |
Novel drug target | Established target |
Trial Name | lidocaine hydrochloride, piroxicam, AK1015,Akten |
blocker (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
Trial Name | ALGRX 3268,Zingo |
blocker (inhibitory) |
inhibitor (inhibitory) |
Trial Name | ALGRX 3268,Zingo |
Novel drug target | Established target |
Trial Name | lidocaine hydrochloride, piroxicam, AK1015,Akten |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
Direct Interaction | yes |
blocker (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Sodium channel alpha subunit blocker |
n/a |
Combination therapy | Lidocaine,Prilocaine |
Combination therapy | Lidocaine,Tetracaine |
antagonist (inhibitory) |
Trial Name | PSD502, lidocaine + prilocaine |
Novel drug target | Established target |
LIDOCAINE | Primary Drug Name |
Year of Approval | approved before 1982 |
Drug Class | anti-arrhythmia agents |
Drug Class | anesthetics, local |
Drug Indications | anesthetic |
Drug Class | Small Molecule |
FDA Approval | approved |
C614 | NCI drug code |
C614 | NCI drug code |
D0X4RN | TTD Drug ID |